A citation-based method for searching scientific literature


List of co-cited articles
24 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia.
Ali R Nasiri, Marcos R Rodrigues, Zongyu Li, Brooks P Leitner, Rachel J Perry. Cancer Metab 2019
19
33

Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Tsugumichi Saito, Shuichi Okada, Eijiro Yamada, Yoko Shimoda, Aya Osaki, Yuko Tagaya, Ryo Shibusawa, Junichi Okada, Masanobu Yamada. Endocr J 2015
20
33

Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Jun Zhou, Jin Zhu, Sheng-Jian Yu, Huai-Lu Ma, Jie Chen, Xiao-Fei Ding, Guang Chen, Yong Liang, Qiang Zhang. Biomed Pharmacother 2020
6
33

Sodium-glucose cotransporters: new targets of cancer therapy?
Ivana Vrhovac Madunić, Josip Madunić, Davorka Breljak, Dean Karaica, Ivan Sabolić. Arh Hig Rada Toksikol 2018
11
33

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Haoyu Kuang, Liya Liao, Hongtao Chen, Qian Kang, Xiaochun Shu, Yanan Wang. Med Sci Monit 2017
23
33

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki, Shinya Sato, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya,[...]. Int J Cancer 2018
42
33

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
33

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
Linda A Villani, Brennan K Smith, Katarina Marcinko, Rebecca J Ford, Lindsay A Broadfield, Alex E Green, Vanessa P Houde, Paola Muti, Theodoros Tsakiridis, Gregory R Steinberg. Mol Metab 2016
56
33

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
33

Obesity: global epidemiology and pathogenesis.
Matthias Blüher. Nat Rev Endocrinol 2019
564
33

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
33

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
189
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
33

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Chikayo Iwaya, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Nobuya Hamanoue, Ryoko Motonaga,[...]. Endocr J 2020
9
33

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh,[...]. Sci Rep 2018
49
33


Functional expression of sodium-glucose transporters in cancer.
Claudio Scafoglio, Bruce A Hirayama, Vladimir Kepe, Jie Liu, Chiara Ghezzi, Nagichettiar Satyamurthy, Neda A Moatamed, Jiaoti Huang, Hermann Koepsell, Jorge R Barrio,[...]. Proc Natl Acad Sci U S A 2015
100
33


Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann,[...]. Eur J Heart Fail 2019
95
33


Metformin and reduced risk of cancer in diabetic patients.
Josie M M Evans, Louise A Donnelly, Alistair M Emslie-Smith, Dario R Alessi, Andrew D Morris. BMJ 2005
16

Repurposing metformin for the prevention of cancer and cancer recurrence.
Brandy M Heckman-Stoddard, Andrea DeCensi, Vikrant V Sahasrabuddhe, Leslie G Ford. Diabetologia 2017
101
16

Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.
Jetty A Overbeek, Marina Bakker, Amber A W A van der Heijden, Myrthe P P van Herk-Sukel, Ron M C Herings, Giel Nijpels. Diabetes Metab Res Rev 2018
18
16


Challenges in systematic reviews that assess treatment harms.
Roger Chou, Mark Helfand. Ann Intern Med 2005
98
16

Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Besmir Nreu, Chiara Montereggi, Edoardo Mannucci, Matteo Monami. Acta Diabetol 2020
4
25

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami. Diabetes Obes Metab 2019
15
16

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan, Shu-Feng Zhou. Clin Exp Pharmacol Physiol 2015
40
16

Insulin Receptor Isoforms in Cancer.
Veronica Vella, Agostino Milluzzo, Nunzio Massimo Scalisi, Paolo Vigneri, Laura Sciacca. Int J Mol Sci 2018
28
16

Review of Associations Between Type 2 Diabetes and Cancer.
Pranay R Bonagiri, Jay H Shubrook. Clin Diabetes 2020
2
50

HbA1C and cancer risk in patients with type 2 diabetes--a nationwide population-based prospective cohort study in Sweden.
Junmei Miao Jonasson, Jan Cederholm, Björn Eliasson, Björn Zethelius, Katarina Eeg-Olofsson, Soffia Gudbjörnsdottir. PLoS One 2012
31
16

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
Sandra De Jonghe, Jim Proctor, Petra Vinken, Bianca Feyen, Inneke Wynant, Dirk Marien, Helena Geys, Rao N V S Mamidi, Mark D Johnson. Chem Biol Interact 2014
28
16

Insulin resistance and cancer: the role of insulin and IGFs.
Sefirin Djiogue, Armel Hervé Nwabo Kamdje, Lorella Vecchio, Maulilio John Kipanyula, Mohammed Farahna, Yousef Aldebasi, Paul Faustin Seke Etet. Endocr Relat Cancer 2013
154
16

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
16

European Society of Cardiology: Cardiovascular Disease Statistics 2017.
Adam Timmis, Nick Townsend, Chris Gale, Rick Grobbee, Nikos Maniadakis, Marcus Flather, Elizabeth Wilkins, Lucy Wright, Rimke Vos, Jeroen Bax,[...]. Eur Heart J 2018
299
16

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Samantha L Bowker, Sumit R Majumdar, Paul Veugelers, Jeffrey A Johnson. Diabetes Care 2006
672
16

Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.
Emi Kawakita, Fan Yang, Asako Kumagai, Yuta Takagaki, Munehiro Kitada, Yasuo Yoshitomi, Takayuki Ikeda, Yuka Nakamura, Yasuhito Ishigaki, Keizo Kanasaki,[...]. Mol Cancer Res 2021
4
25

Fasting serum glucose level and cancer risk in Korean men and women.
Sun Ha Jee, Heechoul Ohrr, Jae Woong Sull, Ji Eun Yun, Min Ji, Jonathan M Samet. JAMA 2005
668
16

Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study.
Hajime Yamagata, Yutaka Kiyohara, Shotaro Nakamura, Michiaki Kubo, Yumihiro Tanizaki, Takayuki Matsumoto, Keiichi Tanaka, Isao Kato, Tomoko Shirota, Mitsuo Iida. Diabetes Care 2005
57
16

Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review.
Yuehong Chen, Liang Du, Ling Li, Jun Ma, Xingyuan Geng, Xun Yao, Guanjian Liu, Xin Sun. J Diabetes 2017
10
16


Adipokine dysregulation and adipose tissue inflammation in human obesity.
Xabier Unamuno, Javier Gómez-Ambrosi, Amaia Rodríguez, Sara Becerril, Gema Frühbeck, Victoria Catalán. Eur J Clin Invest 2018
116
16


Insulin Receptor Isoforms in Physiology and Disease: An Updated View.
Antonino Belfiore, Roberta Malaguarnera, Veronica Vella, Michael C Lawrence, Laura Sciacca, Francesco Frasca, Andrea Morrione, Riccardo Vigneri. Endocr Rev 2017
124
16

Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria.
K Rapp, J Schroeder, J Klenk, H Ulmer, H Concin, G Diem, W Oberaigner, S K Weiland. Diabetologia 2006
194
16

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
Yu-Xiao Yang, Sean Hennessy, James D Lewis. Gastroenterology 2004
253
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.